Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019

Background: Children with Down syndrome (DS) have increased risk of myeloid leukemia (ML), but specific treatment protocols ensure excellent outcome. This study was a retrospective analysis of the treatment results and genetic characteristics of ML of DS (ML-DS) in Poland from 2005 to 2019. Methods: All 54 patients with ML-DS registered in the Polish Pediatric Leukemia and Lymphoma Study Group in analyzed period were enrolled to the study. There were 34 children treated with Acute Myeloid Leukemia–Berlin-Frankfurt-Munster 2004 Interim Protocol (group I) and 20 patients treated with ML-DS 2006 Protocol (group II). In the first protocol, there was reduction of the antracyclines doses and intrathecal treatment for ML-DS compared to non-DS patients. In the second protocol, further reduction of the treatment was introduced (omission of etoposide in the last cycle, no maintenance therapy). Results: Probabilities of 5-year overall survival (OS), event-free survival (EFS), and relapse-free survival in the whole analyzed group were 0.85 ± 0.05, 0.83 ± 0.05, and 0.97 ± 0.03, respectively. No significant differences were found between two protocols in the terms of OS and EFS (0.79 ± 0.07 vs. 0.95 ± 0.05, p = 0.14, and 0.76 ± 0.07 vs. 0.95 ± 0.05, p = 0.12, respectively). All deaths were caused by the treatment-related toxicities. Reduction of the treatment-related mortality was noticed (20% in group I and 5% in group II). The only one relapse in the whole cohort occurred in the patient from group I, older than 4 years, without GATA1 gene mutation. He was treated successfully with IdaFLA cycle followed by hematopoietic stem cell transplantation from matched sibling donor. No significant prognostic factor was found in the study group probably due to low number of patients in the subgroups. Conclusions: The study confirms that the reduced intensity protocols are very effective in ML-DS patients. The only cause of deaths was toxicities; however, systematic decrease of the treatment-related mortality was noticed.

[1]  T. Kitamura,et al.  Association between cardiac rhythm conversion and neurological outcome among cardiac arrest patients with initial shockable rhythm: a nationwide prospective study in Japan. , 2020, European heart journal. Acute cardiovascular care.

[2]  Steven P. Cohen,et al.  Caring for patients with pain during the COVID‐19 pandemic: consensus recommendations from an international expert panel , 2020, Anaesthesia.

[3]  P. Campbell,et al.  Erratum: Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome (Cancer Cell (2019) 36(2) (123–138.e10), (S1535610819302983), (10.1016/j.ccell.2019.06.007)) , 2019 .

[4]  P. Campbell,et al.  Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. , 2019, Cancer cell.

[5]  D. Reinhardt,et al.  Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. , 2017, Blood.

[6]  S. Raimondi,et al.  Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. , 2017, Blood.

[7]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[8]  T. Taki,et al.  Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan , 2016, Pediatric blood & cancer.

[9]  D. Reinhardt,et al.  Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML‐BFM 2004 , 2016, Pediatric blood & cancer.

[10]  R. Pieters,et al.  Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study , 2014, Haematologica.

[11]  A. Curley,et al.  GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. , 2013, Blood.

[12]  D. Johnston,et al.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.

[13]  T. Taki,et al.  Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. , 2012, Blood.

[14]  R. Arceci,et al.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.

[15]  P. Vyas,et al.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. , 2011, Blood.

[16]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[17]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[18]  B. Johansson,et al.  Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. , 2008, Blood.

[19]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[20]  D. Reinhardt,et al.  Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar Blasts , 2005, Klinische Padiatrie.

[21]  A. Teigler‐Schlegel,et al.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. , 2003, Blood.

[22]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[23]  H. Hasle.  Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.

[24]  J. Gurney,et al.  Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. , 1996, Blood.

[25]  A. Zipursky,et al.  Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. , 1994, Leukemia research.